About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

MoonLake Immunotherapeutics (NASDAQ: MLTX) Announces Breakthrough Results for Sonelokimab in Phase 2 Trial

MoonLake Immunotherapeutics (NASDAQ: MLTX) has made significant strides with the successful outcome of their Phase 2 MIRA trial for sonelokimab, setting new benchmarks for the treatment of hidradenitis suppurativa (HS).

MoonLake Achieves Landmark in HS Clinical Development

MoonLake’s global Phase 2 MIRA trial has set an unprecedented milestone in the HS clinical development landscape. The trial, which involved 234 patients, is the first of its kind to report positive top-line results using the Hidradenitis Suppurativa Clinical Response (HiSCR) 75 as its primary endpoint. This stands as a higher measure of clinical response compared to the HiSCR50 measure employed in other clinical trials.

Positive Outcomes with Sonelokimab Highlighted by Clinically Relevant Secondary Endpoints

The trial exhibited a higher proportion of patients achieving HiSCR75 with both the 120mg and 240mg doses of sonelokimab when compared to those on placebo at the 12-week mark. Notably, the 120mg dose had the highest delta on HiSCR75 and HiSCR50, with a 29 ppt delta to placebo on HiSCR75 (p=0.0002) and a 38 ppt delta to placebo on HiSCR50 (p<0.0001).

Other clinically relevant secondary endpoints such as HiSCR90, International Hidradenitis Suppurativa Severity Score System (IHS4), abscess/nodule, draining tunnel counts, and patient-reported pain and quality of life outcomes, also met statistical significance at the 12-week period.

The Unrivalled Safety Profile of Sonelokimab

The safety profile of sonelokimab remained consistent with previous studies, revealing no new safety concerns. It continues to exhibit a favorable safety record, aligning with the known profile of IL-17 inhibitors.

MoonLake’s Aspirations for the Future

Jorge Santos da Silva, the CEO of MoonLake, expresses greater confidence in their ambitious goals after the successful outcome of the Phase 2 MIRA trial. MoonLake aims to raise the bar for HS treatment and establish itself as a leader in the inflammation and immunology space.

The Future of Sonelokimab in Treating Inflammatory Diseases

Sonelokimab demonstrates great promise as a future treatment option. It is currently being evaluated in a Phase 2 trial (ARGO) in patients with active psoriatic arthritis. A comprehensive understanding of its long-term efficacy and safety profile will be achieved with further data collection from the MIRA trial and the adalimumab arms.

MoonLake’s Continued Commitment to Patient Welfare

MoonLake’s dedication to elevating patient outcomes is evident from their pioneering efforts in developing next-level therapies for inflammatory diseases. Their commitment remains steadfast as they aim to meet and beat the best results from pivotal-like trials of competitors.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post MoonLake Immunotherapeutics (NASDAQ: MLTX) Announces Breakthrough Results for Sonelokimab in Phase 2 Trial appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.